STOCKS TELEGRAPH

Tag: TCBP Stock Price

  • TC Biopharm (TCBP) Stock Climbs As Company Unveils Cost-Saving Measures

    TC Biopharm (TCBP) Stock Climbs As Company Unveils Cost-Saving Measures

    Following the announcement of cost-cutting initiatives, TC BioPharm (Holdings) Plc (NASDAQ: TCBP) shares saw a notable increase. TCBP stock was trading at $2.16 as of the most recent market check, representing a significant 32.52% rise on the charts.

    Strategic Cost-Reduction Initiatives

    As part of its broader strategic expansion plan, TC BioPharm is implementing many operational enhancements to increase productivity and financial sustainability. A key element of this initiative, which attempts to transition to a more decentralized corporate model, is outsourcing a number of activities.

    This shift is expected to lead to a more agile organizational structure, reduced overhead costs, and more efficient procedures. As a result of these changes, the company is adopting a Contract Development and Manufacturing Organization (CDMO) model to fulfill the growing manufacturing requirements for future clinical trials.

    This modification will also enable TC BioPharm to research new manufacturing facilities that integrate cutting-edge automated and cell therapy production techniques.

    Workforce Reduction and Financial Impact

    As part of its restructuring efforts, TC BioPharm is reassessing its testing and clinical operations to align with a decentralized drug development framework. As such, TCBP expects to reduce its personnel by about 20 workers, mostly in its production and quality departments.

    It is anticipated that this reduction, which accounts for about half of the company’s workforce, would be mostly finished by the end of the second quarter of 2025. It is anticipated that the cost-cutting initiatives would reduce the business’s primary operating costs by around 55% in comparison to 2024.

    According to TC BioPharm, 2025 will see partial-year savings of $2.1 million, with annualized savings of almost $4.2 million.

    Setting Up for Future Development

    The deliberate move of TC BioPharm toward an outsourced manufacturing model demonstrates its dedication to sustained development and innovation. By cutting internal costs and concentrating on cutting-edge cell therapy production methods, TCBP hopes to fortify its position for upcoming clinical trials.

    Furthermore, as the company gets ready for the ACHIEVE data review—a significant milestone that will guide its next clinical development pathway—TC BioPharm is expanding into additional therapeutic areas.

  • TC Biopharm (TCBP) Shares Surge Following Key Monkeypox Research Collaboration

    TC Biopharm (TCBP) Shares Surge Following Key Monkeypox Research Collaboration

    TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares are experiencing a notable surge on the US stock charts today, rising 13.22% to reach $2.57 following the announcement of a pivotal research collaboration. This agreement positions TCBP to advance its efforts in developing a treatment for Monkeypox, signaling a strategic move in response to ongoing public health challenges.

    TC Biopharm’s Collaboration with a Leading Researcher

    Dr. Carlos Maluquer de Motes, a Reader and Principal Investigator at the University of Surrey in the United Kingdom, is involved in the partnership. The Pirbright Institute, which is well-known for its proficiency in researching viral infections that spread from animals to people, is associated with Dr. Maluquer de Motes.

    He has a PhD in Virology from the University of Barcelona and has conducted important research in prominent universities like the University of Cambridge, Imperial College London, and the University of Pennsylvania. He has concentrated on the ways that herpesviruses evade the immune system and the relationship between innate immunity and the vaccinia virus.

    TCBP: Addressing Viral Infections

    Given the difficulties caused by worldwide pandemics, TC Biopharm is aware of how important gamma delta T-cells are for triggering efficient immune responses to viral infections. Research indicates that these cells are essential not only for preventing infections but also for improving clinical outcomes in affected patients.

    TC Biopharm aims to leverage its lead therapeutic, TCB008, to enhance the immune response by bolstering gamma delta T-cells, potentially improving treatment for Monkeypox and other infectious diseases.

    Future Directions in Prophylactic Applications

    TC Biopharm is also exploring the prophylactic potential of TCB008, aiming to support high-risk patients who are immune-compromised or elderly. The company envisions utilizing TCB008 as an adjunct therapy in hospital settings, thereby addressing the vulnerability of patients whose immune systems are weakened.

    Given his stellar record in infectious illness research, TC Biopharm has decided to follow Dr. Maluquer de Motes’ research strategy following in-depth discussions with subject-matter specialists. TCBP’s dedication to combating new viral dangers has advanced significantly with this partnership.

  • AI Partnership Boosts TC BioPharm (TCBP) Shares As New Project Takes Off

    AI Partnership Boosts TC BioPharm (TCBP) Shares As New Project Takes Off

    On Thursday, TC BioPharm (Holdings) Plc (NASDAQ: TCBP) shares experienced a notable surge on the US stock charts, closing at $6.61, marking an increase of 11.66%. This increasing trajectory comes after the business revealed its most recent artificial intelligence project, which aims to revolutionize cell therapy patient screening procedures.

    TC BioPharm Entered An Strategic Alliance

    A sponsored research agreement has been signed between TC BioPharm and Carnegie Mellon University, a prestigious university recognized for its contributions to computational biology and artificial intelligence.

    Through this partnership, TC BioPharm will collaborate with renowned researcher at the Ray and Stephanie Lane Computational Biology Department, Dr. Wei Wu. Together, they will leverage AI technologies to enhance the donor selection and matching processes, addressing a critical challenge within the cell therapy sector.

    TCBP Addressing the Complexity of Donor Variability

    Dr. Wu’s research primarily focuses on elucidating complex human diseases through integrative methodologies that encompass biology, computational and statistical learning, bioinformatics, and genomics.

    The cell therapy industry faces significant challenges related to donor variability and the accurate prediction of outcomes among diverse patient populations. By employing AI to analyze large datasets, TC BioPharm aims to refine donor screening procedures, ultimately leading to improved manufacturing yields and enhanced patient outcomes.

    Pioneering Advances in Cell Therapy

    It is expected that this endeavor would transform donor selection and patient matching, going beyond current methods based on the human leukocyte antigen (HLA). This novel technique offers a significant market opportunity and has the potential to be widely applied in the biopharmaceutical sector as well as within contract development and manufacturing organizations (CDMOs).

    TC BioPharm’s partnership with Carnegie Mellon University marks a significant step in addressing this ‘big data problem,’ and the collaboration is poised to yield substantial breakthroughs in medical and scientific fields. The excitement surrounding this endeavor reflects the immense potential of artificial intelligence to reshape the landscape of cell therapy and improve patient care outcomes.

  • What Instigated After-Hour Rise In TC Biopharm (TCBP) Stock

    What Instigated After-Hour Rise In TC Biopharm (TCBP) Stock

    TC Biopharm (Holdings) Plc (NASDAQ: TCBP) experienced a notable upswing of 8.43%, reaching $2.83 in the extended trading session on Monday. In the regular hours, TC Biopharm recorded a modest ascent of 1.16%, concluding the session at $2.61. This positive momentum in TCBP shares was instigated by the establishment of a novel division within the organization.

    TC BioPharm (TCBP) has officially unveiled the establishment of a Commercial Development Division, a strategic initiative helmed by Dr. Lauren Bor, PhD. This newly formed division is poised to concentrate on streamlining the production processes of TCB-008, with a keen anticipation of ACHIEVE data in 2024.

    Furthermore, it will address the recent IND clearance for TCB-008 in the United States. The division’s responsibilities extend to devising a clear regulatory pathway for commercialization, researching innovative technologies to enhance future manufacturing efficiencies, and exploring collaborative ventures with external entities to leverage the company’s GMP licensed facility for monetization purposes.

    The inception of this new division is a proactive measure by TC BioPharm, positioning the company for the forthcoming trial data and regulatory commercialization filings, a focal point for regulators in the realm of cell therapy. This strategic move is designed to circumvent potential supply-chain setbacks, leveraging the robust manufacturing capabilities of TCBP.

    The Commercial Development Division, under the leadership of Dr. Bor, will not only oversee the production and manufacturing of cell therapies but will also strive to elevate processes to the highest standards, ensuring optimal economics for large-scale commercialization.

    This heightened oversight is expected to yield a more efficacious product in the field of cell therapy, fortifying TCBP’s position as it endeavors to lead the way in pioneering a potent class of gamma-delta T cell therapies for cancer treatment.

    Dr. Bor, who joined TC BioPharm in 2019, has been instrumental in advancing the company’s Unmodified cryopreserved Vγ9Vδ2 T cell manufacturing process, specializing in process development and technology transfer within her research domain.